Saphnelo (anifrolumab-fnia) - AstraZeneca
Efficacy of Anifrolumab Across Multiple Organ Systems in Patients with Moderate to Severe Systemic Lupus Erythematosus: A Post-Hoc Analysis of the Phase III AZALEA trial (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2200; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available 
Clinical • P3 data • Retrospective data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
https://eppro02.ativ.me/web/page.php?nav=false&page=Session&project=ACR26&id=3570188
 
Jiuliang Zhao, PhD
 
Sep 8, 2026
 
Prev Next